Ernexa Therapeutics Inc.
ERNA
$4.27
-$0.03-0.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -99.83% | 201.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -99.83% | 201.23% |
| Cost of Revenue | -- | -- | -- | -100.00% | -117.54% |
| Gross Profit | -- | -- | -- | -99.77% | 404.44% |
| SG&A Expenses | -30.98% | -47.53% | -60.69% | -67.25% | -54.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.20% | -31.19% | -47.75% | -52.56% | -44.69% |
| Operating Income | 0.22% | 28.60% | 45.98% | 51.17% | 46.50% |
| Income Before Tax | 71.71% | 75.08% | 68.26% | 59.23% | -82.53% |
| Income Tax Expenses | -382.35% | -373.53% | -250.00% | 86.67% | 780.00% |
| Earnings from Continuing Operations | 71.95% | 75.30% | 68.38% | 59.18% | -82.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.95% | 75.30% | 68.38% | 59.18% | -82.71% |
| EBIT | 0.22% | 28.60% | 45.98% | 51.17% | 46.50% |
| EBITDA | -0.15% | 28.39% | 45.92% | 51.18% | 46.61% |
| EPS Basic | 99.05% | 98.70% | 97.04% | 95.72% | -18.88% |
| Normalized Basic EPS | 96.52% | 96.65% | 93.62% | 91.32% | 67.78% |
| EPS Diluted | 99.05% | 98.70% | 97.04% | 95.72% | -18.88% |
| Normalized Diluted EPS | 96.52% | 96.65% | 93.62% | 91.32% | 67.78% |
| Average Basic Shares Outstanding | 465.66% | 507.21% | 592.99% | 1,254.69% | 708.51% |
| Average Diluted Shares Outstanding | 465.66% | 507.21% | 592.99% | 1,254.69% | 708.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | 1.00% |